You are here

U.S. Multicenter Study of taTME for Rectal Cancer Update

U.S. Multicenter Study of taTME for Rectal Cancer Update | ASCRS

Transanal Total Mesorectal Excision (taTME) is a novel minimally invasive surgical approach for the treatment of rectal cancer. Since the first taTME clinical report in 2009, the approach has been adopted increasingly worldwide. While preliminary outcomes of taTME are encouraging, they are limited to case series and one international registry.

The US Multicenter Study of taTME for rectal cancer opened for enrollment in May 2017 (clinicaltrials.gov NCT03144765). This is a 5-year Phase II clinical trial investigating taTME with laparoscopic or robotic assistance in patients with resectable rectal cancer and who are eligible for sphincter preservation.

The trial is led by Patricia Sylla, MD at Mount Sinai Hospital and is funded in part by a generous grant from the Research Foundation of the American Society of Colon and Rectal Surgeons (RF ASCRS). For more information, please visit the taTME Multicenter Study web page.